Liquidia Technologies, Inc.
(NASDAQ : LQDA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-10.17%132.810.6%$1507.80m
PFEPfizer Inc.
-1.62%43.850.9%$1018.02m
MRKMerck & Co., Inc.
-2.49%76.510.6%$1010.61m
ABBVAbbVie, Inc.
-2.38%85.622.2%$531.70m
LLYEli Lilly and Company
-2.49%112.001.0%$505.80m
BMYBristol-Myers Squibb Company
-2.82%52.131.4%$488.82m
NVSNovartis AG Sponsored ADR
-1.13%87.400.2%$229.97m
AZNAstraZeneca PLC Sponsored ADR
-0.20%39.161.3%$204.11m
GSKGlaxoSmithKline plc Sponsored ADR
-0.87%37.610.2%$157.71m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.51%46.530.1%$72.80m
SNYSanofi Sponsored ADR
-1.83%44.070.2%$46.08m
LCILannett Company, Inc.
-4.53%4.8537.0%$8.90m
AKTXAkari Therapeutics Plc Sponsored ADR
4.12%1.771.7%$0.02m

Company Profile

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. The collaborates with leading pharmaceutical companies to apply its PRINT technology across a wide range of therapeutic areas, molecule types and routes of administration. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.